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Oropharyngeal mucositis–specific 
quality-of-life measure in patients with 
cancer therapy
Key Messages
1. The oropharyngeal mucositis–
specific quality-of-life measure 
(OMQoL) is the first patient-
reported measure specific for 
oropharyngeal mucositis (OM) 
and has good reliability and 
validity. It may be useful for 
assessing the overall impact 
of OM from the perspective of 
patients.
2. The OMQoL may provide a 
common platform for clinicians 
to assess, care for, and treat 
patients with OM.
Hong Kong Med J 2010;16(Suppl 3):S42-6
Introduction
Oropharyngeal mucositis (OM) is an acute inflammatory and ulcerative oral 
complication that commonly occurs during cancer therapy. It can cause profound 
impairment of health-related quality of life (HRQoL).1 Currently, there is no 
measure specific to OM that can address health status particularly relevant 
to OM patients during cancer therapy. The objectives of this study were to 
develop an OM-specific HRQoL measure (OMQoL) and to evaluate whether 
its psychometric properties would be adequate to support its use for assessing 
patients with cancer therapy-induced OM.
Method
This study was conducted from October 2005 to March 2007 in two university-
affiliated hospitals and one regional hospital in Hong Kong following approval 
from their Institutional Review Boards. In accordance with the Declaration 
of Helsinki, all subjects provided written informed consent before enrolment. 
Subjects were over 18 years old and diagnosed with haematological malignancies 
or solid tumours. They were treated with one of the following cancer therapies: 
stomatotoxic chemotherapy (eg adriamycin, etoposide, melphalan, methotrexate, 
or 5-fluorouracil), head/neck irradiation, concomitant head/neck irradiation and 
chemotherapy, or high-dose myeloablative chemotherapy and/or total body 
irradiation (TBI) followed by haematopoietic stem cell transplant (HSCT). 
Convenience sampling was used to recruit patients.
 The OMQoL was developed and validated in three stages: (1) to perform item 
generation, (2) to perform item reduction and scale generation, and (3) to assess 
the construct validity of the developed scale.2
Stage 1: item generation
Exploratory, in-depth qualitative interviews were carried out with 23 patients 
who had experienced OM in order to identify relevant areas, which enabled a 
large number of candidate questionnaire items to be generated.3 Three of the 
investigators independently selected and devised questionnaire items from the 
qualitative review. All items were formulated both in English and Chinese by a 
linguistics expert and two bilingual investigators. The degree to which OMQoL 
elements including individual items, response formats and instructions are 
relevant to and representative of the targeted construct were determined by focus 
group discussion (n=13) and expert content review (n=7).
Stage 2: item reduction and scale generation
In order to determine the psychometric properties of the OMQoL, the preliminary 
version developed in stage 1 was administered to 210 subjects with more than 
or equal to World Health Organization (WHO) grade-I OM during their cancer 
therapies to test factor structure, internal consistency and scaling properties. A 
total of 47 subjects were selected at random to fill in the OMQoL again within 3 
days in order to assess the reliability of the OMQoL over time. An exploratory 
factor analysis was undertaken to extract factors in order to explore how the 
items of the OMQoL were combined into relevant subscales. Cronbach’s alpha 
coefficient was used to assess the internal consistency reliability for the subscales 
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total. The test-retest pairs for each individual item were 
analysed using a Weighted Kappa coefficient,3 and the 
test-retest analysis of the subscale total scores was about 
performed using intraclass correlation.4 Scale level analysis 
was evaluated by the floor and ceiling effects, as well as by 
Rasch analysis.
Stage 3: assessing construct validity
A total of 137 patients completed the OMQoL and the 
Chinese version of the European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire 
– Core 30 (EORTC QLQ-C30 [Ch]) in a random order at 
baseline and twice a week until 3 weeks after completion 
of stomatotoxic chemotherapy or conditioning regimen for 
hematopoietic stem cell transplantation (HSCT) [D1, 4, 7, 
10, 14, 17, 21, 24, 28], or at baseline and then weekly until 
3 weeks after completion of head/neck irradiation (D1, 7, 
14, 21, 28, 35, 42, 49, 56, 63, 70), along with concurrent 
measures of OM using the WHO 0-IV grading system 
and OM-related symptoms using a 10-cm visual analogue 
scale.
 The mean peak and the area-under-the-curve (AUC) 
scores for the OMQoL, OM-related pain and symptoms, 
and EORTC QLQ-C30 (Ch) were calculated prior to 
construct validity testing, in order to adjust unequal time 
points of assessments for different cancer therapy groups. 
Convergent validities were tested by calculating Pearson’s 
correlation coefficient for correlations between the OMQoL 
subscales and OM-related symptoms peak and AUC scores. 
Known-groups validity was evaluated by comparing the 
OMQoL subscale peak and AUC scores among patients 
with different levels of OM (WHO grade 0, I, II, III, or 
IV) and different types of cancer therapy, using a one-way 
ANOVA given normally distributed data.
 The responsiveness of the OMQoL to change over time 
was assessed by comparing the OMQoL subscale change 
scores among patients with no increment (group A), <2 
grades of increment (group B), and ≥2 grades of increment 
(group C) of OM using the WHO grading system from 
day 1 to peak, as well as among patients with no reduction 
(group D), <2 grades of reduction (group E), and ≥2 grades 
of reduction (group F) of OM from peak symptoms to the 
last day of data collection. Change of scores in the OMQoL 
subscales among these subgroups were compared using 
one-way ANOVA given normally distributed data. The 
responsiveness of the OMQoL to change over time was also 
evaluated by relating the OMQoL subscales AUC scores 
to WHO OM AUC scores using the Spearman correlation 
test. It was predicted that there would be a moderately high 
correlation between the OMQoL and WHO AUC scores.
Results
Stage 1: item generation
The mean age of the 11 female and 12 male patients 
was 42±13 (range, 21-58) years. Nine (39%) patients 
had nasopharyngeal cancer and seven (30%) had acute 
lymphoblastic leukaemia. The respondents were well 
distributed with respect to cancer treatment modality. The 
analysis of respondent interviews resulted in the generation 
of 171 items. Three investigators went on to independently 
select and devise questionnaire items from these 171 items, 
which were then discussed and scrutinised for repetition 
and ambiguity until a final set of items was agreed upon. 
After removal of duplicate and idiosyncratic items, the 
selection process yielded 63 items for the first version of the 
OMQoL. Using focus group discussion and expert content 
review, items were reduced to 41 items. A four-point 
Likert scale with descriptors (1=not at all, 2=a little bit, 
3=quite a bit, 4=very much) response format was selected 
because previous HRQoL studies indicated this to the most 
appropriate scoring format for such an instrument.5
Stage 2: item reduction and scale generation
The mean age of the 120 female and 90 male patients was 
51±12 (range, 21-84) years; 91 (43%) of the patients had 
nasopharyngeal cancer. Of the 210 patients, 76 (36%) were 
treated with stomatotoxic chemotherapy, and 71 (34%) with 
concomitant head/neck irradiation and/or chemotherapy. 
Patients were quite evenly distributed with respect to OM 
severity, except for WHO grade IV. Factor analysis of these 
41 items resulted in four subscales, which contributed 31 
items depicting problems with: symptoms (9 items), diet 
(10 items), social function (7 items), and swallowing (5 
items). As shown in Table 1, the factorial structure was 
satisfactory with a loading >0.40 on each subscale for all 
items. Thus, all corrected item scales were higher than 0.40 
(r=0.457-0.874). The internal consistency and reliability of 
each subscale was high with Cronbach alpha coefficients 
ranging from 0.906 to 0.934. The test-retest reliability of the 
individual items using Weighted Kappa was good (Kappa 
values, 0.610-0.895). The intraclass correlation results for 
the subscale totals were all in excess of 0.70 (0.864-0.934). 
The floor effect was modest. Rasch analysis supported the 
present four category scoring system for the OMQoL.
Stage 3: assessing construct validity
The mean age of 65 female and 72 male patients was 
49.6±10.9 (range, 18-78) years; 63 (46%) had head/neck 
cancer. Of the 137 patients, 61 (45%) were treated with 
stomatotoxic chemotherapy, and 60 (44%) with head/neck 
irradiation and/or chemotherapy. The frequency of OM 
was 90%; 11%, 29%, 32%, and 18% had WHO grades 
I, II, III, and IV, respectively. As shown in Table 2, the 
OM-related symptom scores correlated highly with the 
OMQoL, confirming its convergent validity (r=-0.724 
to -0.971, P<0.01). Moderate correlations between the 
subscales of the OMQoL and EORTC QLQ-C30 (Ch) were 
indicative of good concurrent validity (r=0.450-0.724, 
P<0.01). The OMQoL could be used to distinguish patients 
with different OM severities (P<0.01) and types of cancer 
therapy (P<0.01), providing evidence of good known-group 
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validity. Patients with OM symptoms who had ≥2 grades of 
increment from day 1 to peak and ≥2 grades of reduction 
from peak to the last day of data collection had a larger 
based on change in OMQoL scores. The changes in effects 
sizes corresponding to changes in OM curves indicate that 
the OMQoL is responsive to changes in OM status.
Discussion
Oropharyngeal mucositis can have a significant impact on 
multiple facets of HRQoL to varying degrees.1 Clinicians 
must consider other aspects of OM in addition to about the 
physical injury. In this era of patient-centred approaches in 
treatment and care, a better understanding of the HRQoL 
changes associated with OM viewed from the patient’s 
perspective is needed for informed medical decisions and 
to improve clinical outcomes. The OMQoL developed 
in this study addresses experiences judged to be of great 
importance to patients with OM. Content validity has been 
addressed by developing items on the basis of in-depth 
qualitative interviews, focus groups and expert content 
review.
 Our factor analysis supported the creation of symptoms, 
diet, social function, and swallowing subscales. Such 
dimensions of OMQoL were distinctive and of special 
importance in OM. The OMQoL subscales had a high 
degree of internal consistency, confirming reliability. In 
addition, the test-test reliabilities were good, meeting 
all Weight Kappa and intraclass correlation coefficient 
requirements.3,4 The symptoms scale consisted of nine 
items addressing aspects of pain, oedema, burning and 
bleeding in relation to OM. The diet scale included 10 items 
assessing different degrees of dietary and eating problems. 
The social function scale included seven items assessing 
problems with communicating to others and embarrassment 
at mealtimes with family and friends. The swallowing scale 
consisted of five items related to swallowing problems. The 
present four category scoring system for the OMQoL was 
found to be valid in terms of Rasch modelling. The floor 
Table 1. Exploratory factor analysis and reliability analysis of the 31-item oropharyngeal mucositis–specific quality-of-life 
measure (n=210)*
Item Exploratory factor analysis Internal consistency Test-retest reliability
Factor 1 Factor 2 Factor 3 Factor 4
Corrected 
item–total
correlation Cronbach α
α if item 
deleted
Weighted
Kappa
Intraclass 
correlation
Symptoms
1 I have swelling inside my mouth 0.550 0.651 0.916 0.910 0.688 0.864
2 I have mouth ulcer 0.645 0.657 0.909 0.718
3 Mouth pain makes me distressed 0.788 0.346 0.874 0.893 0.754
4 I have oozing/bleeding on my lips, or inside my mouth 0.602 0.457 0.920 0.697
5 I feel discomfort while tooth brushing/mouth rinsing 0.655 0.695 0.907 0.649
6 Mouth pain makes me have trouble sleeping 0.525 0.312 0.758 0.903 0.791
7 I have mouth pain 0.868 0.353 0.832 0.897 0.687
8 I have burning sensation inside my mouth 0.569 0.353 0.742 0.904 0.610
9 I have difficulty in opening my mouth 0.448 0.656 0.909 0.792
Diet
10 I am unable to enjoy food 0.802 0.813 0.929 0.917 0.762 0.914
11 I reduce outside social dining due to mucosal discomfort 0.558 0.681 0.924 0.757
12 My saliva becomes thick/sticky and need to spit out frequently 0.491 0.335 0.680 0.924 0.775
13 I have taste changes 0.690 0.621 0.927 0.718
14 Eating difficulty makes me distressed 0.463 0.822 0.916 0.841
15 I use longer time to drink/eat 0.465 0.745 0.920 0.835
16 I have weight loss 0.663 0.598 0.928 0.895
17 I modify my diet (eg food type, texture and size) 0.859 0.802 0.918 0.742
18 I reduce my soft/solid food intake 0.553 0.729 0.921 0.808
19 I worry about my inadequate nutritional intake 0.720 0.745 0.921 0.762
Social function
20 I speak with lower quality/voice 0.687 0.785 0.934 0.924 0.726 0.934
21 I have difficulty in talking 0.640 0.815 0.921 0.826
22 I need to use other means (eg paper/pen, body language) to communicate with others 0.742 0.742 0.928 0.698
23 I feel embarrassed at mealtimes with my family/friends 0.528 0.702 0.932 0.722
24 Speaking difficulty makes me distressed 0.726 0.864 0.916 0.895
25 I do not want to talk to others (including talking on phone) due to mouth discomfort 0.715 0.790 0.924 0.786
26 I have my expression (including smiling to others) and communication affected 0.680 0.812 0.922 0.800
Swallowing 
27 I have throat discomfort 0.642 0.709 0.906 0.896 0.756 0.896
28 I have difficulty in swallowing liquids (eg water, juice, soup) 0.686 0.797 0.878 0.643
29 I have difficulty in swallowing soft/solid food 0.460 0.764 0.886 0.757
30 I feel easily choked while swallowing 0.500 0.732 0.891 0.684
31 I have difficulty in swallowing saliva 0.751 0.827 0.871 0.695
Explained variance 50.258 4.986 4.303 3.252
Alpha=0.971, standardised item alpha=0.970
* Loadings >0.30 are presented. Loadings >0.40 are in bold type
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effect of the sample was modest, while the ceiling effect 
was negligible.
 The overall correlation coefficients between the OMQoL 
subscale and OM-related pain and symptom scores were 
very high (0.724-0.971), confirming the convergent validity 
of the OMQoL to a high degree. The good convergent 
validity indicated that the OMQoL can address dimensions 
of health status that are particularly relevant to patients with 
OM. Such dimensions of oropharyngeal symptoms and 
function, nutrition, and social contact were distinctive and 
of vital importance in OM. Moderate correlations between 
the OMQoL and EORTC QLQ-C30 (Ch) indicated that 
these two scales measure concepts that were related but 
distinguishable and not redundant, thus confirming the 
concurrent validity.
 In addition to convergent and concurrent validities, the 
construct validity was also supported by comparing the 
OMQoL subscale scores for sub-populations that varied 
clinically. Patients with severe OM and those treated with 
head/neck irradiation and/or chemotherapy scored lower 
on the OMQoL subscales than patients with mild OM and 
those receiving stomatotoxic chemotherapy alone. There 
were statistically significant corresponding changes in 
scores for the OMQoL subscales among varying levels of 
changes in WHO OM scores. Additionally, the correlations 
between changes in the OMQoL subscale and WHO OM 
AUC scores from day 1 to the last day of data collection 
were high (0.733-0.877). These results suggest that the 
OMQoL was responsive to changes over time.
Conclusion
The OMQoL was developed as a patient perspective 
questionnaire to measure a range of important aspects of 
HRQOL that can address health status particularly relevant 
to patients with OM. The OMQoL is reliable and valid and 
Item Exploratory factor analysis Internal consistency Test-retest reliability
Factor 1 Factor 2 Factor 3 Factor 4
Corrected 
item–total
correlation Cronbach α
α if item 
deleted
Weighted
Kappa
Intraclass 
correlation
Symptoms
1 I have swelling inside my mouth 0.550 0.651 0.916 0.910 0.688 0.864
2 I have mouth ulcer 0.645 0.657 0.909 0.718
3 Mouth pain makes me distressed 0.788 0.346 0.874 0.893 0.754
4 I have oozing/bleeding on my lips, or inside my mouth 0.602 0.457 0.920 0.697
5 I feel discomfort while tooth brushing/mouth rinsing 0.655 0.695 0.907 0.649
6 Mouth pain makes me have trouble sleeping 0.525 0.312 0.758 0.903 0.791
7 I have mouth pain 0.868 0.353 0.832 0.897 0.687
8 I have burning sensation inside my mouth 0.569 0.353 0.742 0.904 0.610
9 I have difficulty in opening my mouth 0.448 0.656 0.909 0.792
Diet
10 I am unable to enjoy food 0.802 0.813 0.929 0.917 0.762 0.914
11 I reduce outside social dining due to mucosal discomfort 0.558 0.681 0.924 0.757
12 My saliva becomes thick/sticky and need to spit out frequently 0.491 0.335 0.680 0.924 0.775
13 I have taste changes 0.690 0.621 0.927 0.718
14 Eating difficulty makes me distressed 0.463 0.822 0.916 0.841
15 I use longer time to drink/eat 0.465 0.745 0.920 0.835
16 I have weight loss 0.663 0.598 0.928 0.895
17 I modify my diet (eg food type, texture and size) 0.859 0.802 0.918 0.742
18 I reduce my soft/solid food intake 0.553 0.729 0.921 0.808
19 I worry about my inadequate nutritional intake 0.720 0.745 0.921 0.762
Social function
20 I speak with lower quality/voice 0.687 0.785 0.934 0.924 0.726 0.934
21 I have difficulty in talking 0.640 0.815 0.921 0.826
22 I need to use other means (eg paper/pen, body language) to communicate with others 0.742 0.742 0.928 0.698
23 I feel embarrassed at mealtimes with my family/friends 0.528 0.702 0.932 0.722
24 Speaking difficulty makes me distressed 0.726 0.864 0.916 0.895
25 I do not want to talk to others (including talking on phone) due to mouth discomfort 0.715 0.790 0.924 0.786
26 I have my expression (including smiling to others) and communication affected 0.680 0.812 0.922 0.800
Swallowing 
27 I have throat discomfort 0.642 0.709 0.906 0.896 0.756 0.896
28 I have difficulty in swallowing liquids (eg water, juice, soup) 0.686 0.797 0.878 0.643
29 I have difficulty in swallowing soft/solid food 0.460 0.764 0.886 0.757
30 I feel easily choked while swallowing 0.500 0.732 0.891 0.684
31 I have difficulty in swallowing saliva 0.751 0.827 0.871 0.695
Explained variance 50.258 4.986 4.303 3.252
Alpha=0.971, standardised item alpha=0.970
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Table 2. Convergent and concurrent validities: Pearson correlation between oropharyngeal mucositis–specific quality-of-life 
measure (OMQoL) and comparator measures (n=137)
* Correlation is significant at the 0.01 level (2-tailed)
† Calculated by Spearman rank correlation; highest correlation coefficients are in bold type
‡ EORTC-QLQ C30 (Ch) denotes Chinese version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30
Paramter OMQoL subscale
Symptom Diet Social function Swallowing
Peak Area 
under 
the curve
Peak Area 
under 
the curve
Peak Area 
under 
the curve
Peak Area 
under 
the curve
World Health Organization OM 
grade†
-0.090* -0.733* -0.863* -0.844* -0.856* -0.843* -0.872* -0.877*
OM-related symptoms
Mouth pain -0.945* -0.835* -0.880* -0.800* -0.971* -0.831* -0.911* -0.886*
Throat pain -0.910* -0.825* -0.897* -0.814* -0.871* -0.830* -0.941* -0.923*
Difficulty in eating/chewing -0.921* -0.825* -0.927* -0.854* -0.888* -0.862* -0.951* -0.943*
Difficulty in swallowing -0.903* -0.808* -0.926* -0.836* -0.893* -0.848* -0.959* -0.935*
Difficulty in speaking -0.915* -0.819* -0.878* -0.780* -0.941* -0.926* -0.919* -0.884*
Mouth dryness -0.844* -0.724* -0.872* -0.763* -0.821* -0.766* -0.885* -0.852*
EORTC-QLQ C30 (Ch)‡
Global health status/quality of life 0.547* 0.450* 0.559* 0.531* 0.500* 0.504* 0.514* 0.495*
Physical functioning 0.688* 0.564* 0.719* 0.648* 0.739* 0.680* 0.717* 0.641*
Role functioning 0.660* 0.572* 0.726* 0.601* 0.659* 0.558* 0.686* 0.574*
Emotional functioning 0.665* 0.493* 0.678* 0.641* 0.705* 0.655* 0.645* 0.618*
Cognitive functioning 0.689* 0.594* 0.704* 0.675* 0.724* 0.731* 0.700* 0.707*
Social functioning 0.604* 0.495* 0.695* 0.547* 0.633* 0.572* 0.628* 0.554*
Changing of body weight (D1-peak) 
[n=97]
0.628* 0.683* 0.658* 0.692* 0.636* 0.722* 0.673* 0.734*
can be used as a HRQOL assessment for cancer patients 
with OM.
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